Clinical Study
Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330
Table 2
Nonthromboembolic adverse events for cohort A and B patients in RTOG 0330.
| | Cohort A Grade | Cohort B Grade |
| Adverse event | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| Auditory/ear | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Blood/bone marrow | 2 | 1 | 5 | 5 | 0 | 2 | 0 | 0 | 0 | 0 | Cardiac arrhythmia | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | Cardiac general | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Coagulation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Constitutional symptoms | 3 | 8 | 3 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | Dermatology/skin | 2 | 7 | 2 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | Endocrine | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Gastrointestinal | 2 | 8 | 3 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | Hemorrhage/bleeding | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | Infection | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | Lymphatics | 5 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Metabolic/laboratory | 3 | 5 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | Musculoskeletal/soft tissue | 0 | 4 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | Neurology | 2 | 4 | 3 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | Ocular/visual | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | Pain | 2 | 8 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | Pending | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | Pulmonary/upper respiratory | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Sexual/reproductive function | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Worst nonhematologic | 1 | 5 | 7 | 1 | 0 | 1 | 2 | 4 | 0 | 0 | (%) | (6.7) | (33.3) | (46.7) | (6.7) | (0.0) | (14.3) | (28.6) | (57.1) | (0.0) | (0.0) |
| Worst overall | 1 | 2 | 6 | 6 | 0 | 1 | 2 | 4 | 0 | 0 | (%) | (6.7) | (13.3) | (40.0) | (40.0) | (0.0) | (14.3) | (28.6) | (57.1) | (0.0) | (0.0) |
|
|